NAGA-GROUP-AG
13.1.2022 15:24:10 CET | Business Wire | Press release
NAGA Group AG (XETRA: N4G, ISIN: DE000A161NR7), provider of the social network for trading, cryptocurrencies and payments NAGA.com, has exceeded its revenue guidance for 2021 according to unaudited preliminary figures.
Consolidated group revenue more than doubled to around EUR 55.3 million compared to previous year (2020: EUR 24.4 million). The strong growth is underlined by a record EBITDA of EUR 12.8 million, which is also almost a doubling compared to 2020 (EUR 6.6 million). Furthermore, NAGA reports that over 277,000 new accounts joined its trading platform, a 128% increase compared to last year (2020: 122,000 new accounts).
Traded volume in 2021 reached EUR 250 billion for the first time, which means that the company was also able to double this metric compared to 2020 (EUR 121 billion). In addition, NAGA executed more than 10 million real-money transactions, an increase of 60% compared to 2020 (6.3 million). Notably, the strongest growth metric is the copy-trading activity. In 2021 NAGA saw over 4.8 million trades copied via its unique Auto Copy tool, that is almost tripling compared to 2020 (1.7 million copied trades).
"2021 was a fantastic year for NAGA. We have delivered another record year and achieved several milestones along the way. The investments in growth and the continuous acceleration of our marketing activities have paid off. Additionally, we have launched great products such as NAGA Pay, improved our platform and welcomed strategic investors to our cap table. 2022 will be another eventful year. We expect to be among the fastest growing neo-brokers, by gaining further market share in existing markets but also by expanding into new markets, while also increasingly focusing on the crypto and DeFi space with our brand-new platform NAGAX", comments Benjamin Bilski, Founder and CEO of NAGA.
Launch of NAGAX in Q1 2022
NAGA announces the launch of a brand-new social trading platform focused on cryptocurrencies: NAGAX,
The platform aims to offer:
- A unique Web3 social trading experience
- A spot exchange supporting over 700 tradable assets
- A futures and derivatives exchange
- A crypto-currency wallet with top level security
- An inbuilt NFT platform
- A staking platform
- A launchpad for promising projects
- Educational video content in the Learn-platform against rewards
The platform will offer a globally unique "Web3 Social Investing Feed" which automatically converts each user generated content on the platform into an NFT that can be monetized.
"With NAGA we have built one of the most innovative brokerage platforms in the industry - driven by social interaction and ultimately copy trading. Also, we gained unique insights between content creators and influencers and their needs. However, we believe that Decentralized Finance (DeFi) will be one of the strongest growing segments in the financial space and therefore will combine our knowledge with all our innovation capabilities and breadth of experience. With our brand new Web3 Social Investing Feed we believe to set a new standard in the world of financial influencers, improving their capabilities to serve their audience better, while offering instant monetisation of their content bypassing the middleman", says Bilski .
He also adds: "A financial influencer, for example, who offers premium content such as trading signals or technical analysis, posts the content and can directly set a price and availability. The post is automatically converted to an NFT. Any user who has access to an Ethereum-based wallet can unlock the content immediately. Each content is thus tokenized and can even be traded as an NFT itself. And of course, NAGAX will offer traders the opportunity to copy influencers' crypto trades for more than 700 assets via the social feed. The crypto world is highly fragmented. Crypto traders are literally forced to follow and join multiple groups and accounts across different platforms in order not to miss out. Crypto influencers, on the other hand, have to manage a wide variety of channels and monetization streams. Hence, we believe that our concept of content, direct monetization for influencers and copy trading on cryptocurrencies will experience great demand and will create a strong new source of revenue for NAGA."
The first version of NAGAX will launch within Q1 2022.
NAGAs CEO Benjamin Bilski will hold a recorded webinar on Friday the 14th of January at 15:00 (CET) and present NAGAX in detail. To join please visit https://naga.com/academy/webinars/936
###
About NAGA
NAGA is an innovative fintech company that has developed a socially enhanced financial system that creates a unified and seamless experience across personal finance and investing. Its proprietary platform offers a range of products ranging from trading, investing, and cryptocurrencies to a physical VISA card and social investing features such as a Feed, a Messenger and Auto-Copy. NAGA is a synergistic all-in-one solution that's accessible and inclusive, and that provides a better way to trade, invest, connect, earn, acquire and pay, across both fiat and crypto.
| Language: | English |
| Company: | The NAGA Group AG |
| Hohe Bleichen 12 | |
| 20354 Hamburg | |
| Germany | |
| E-mail: | info@naga.com |
| Internet: | www.naga.com |
| ISIN: | DE000A161NR7 |
| WKN: | A161NR |
| Indices: | Scale 30 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Hamburg, Munich, Stuttgart, Tradegate Exchange |
View source version on businesswire.com: https://www.businesswire.com/news/home/20220113005574/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom